

#### Role

Quod is advising GlaxoSmithKline (GSK) on the development of a new Cephalosporins ("Cephs") Energy Centre, within the wider GSK manufacturing facility in Ulverston. This will replace the existing Energy Centre that serves GSK operations.

Our role was to define the planning strategy for the project, and work closely with the project team and South Lakeland District Council we coordinated, a full planning application including supporting planning justification.

Changes in energy and utility demands over the years, as well as advancements in technologies, have meant that the existing Energy Centre serving the GSK site is oversized, inefficient and outdated. The existing boiler plant is nearing the end of its useful life, and the facility is unlikely to represent the best available technology for any further improvements in the reduction and control of air emissions.

The new Energy Centre will generate and provide energy to power the manufacturing operations being undertaken by GSK at their Ulverston site. It will replace the existing Energy Centre, which is inefficient and outdated.

The construction of a new facility is the most operationally efficient solution and will deliver significant improvements in terms of environmental performance, including a reduction in emissions affecting both air quality and noise.

# **Description**

**Construction of a new Energy Centre** 

### Client

GlaxoSmithKline

# **Planning Authority**

**South Lakeland District Council** 

### **Expertise**

Planning

CIL

**Environmental Planning** 

**Development Economics** 

Socio-economic

Infrastructure

**Strategic Land Promotion** 

Regeneration

CPO

### **Project Type**

Infrastructure

Major Mixed Use

Residential

**Retail & Commercial**